- Home
- SG vs QURE Comparison
SG vs QURE Comparison
Compare SG & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SG | QURE |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 820.3M | 663.4M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SG | QURE |
|---|---|---|
| Price | $5.29 | $15.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 14 |
| Target Price | $8.55 | ★ $45.42 |
| AVG Volume (30 Days) | 3.9M | ★ 4.5M |
| Earning Date | 05-07-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $679,474,000.00 | $13,107,000.00 |
| Revenue This Year | $8.30 | $126.14 |
| Revenue Next Year | $7.82 | $395.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.39 | N/A |
| 52 Week Low | $5.00 | $7.76 |
| 52 Week High | $27.15 | $71.50 |
Technical Indicators
Market Signals| Indicator | SG | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 44.40 |
| Support Level | $5.10 | $13.19 |
| Resistance Level | $6.16 | $16.62 |
| Average True Range (ATR) | 0.36 | 1.72 |
| MACD | 0.01 | 0.28 |
| Stochastic Oscillator | 16.19 | 66.30 |
Price Performance
Historical ComparisonAbout SG Sweetgreen Inc.
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.